Bio-Path (NASDAQ: BPTH) notifies SEC of late Q1 2026 10-Q filing

Rhea-AI Filing Summary

Bio-Path Holdings, Inc. filed a Form 12b-25 notifying the SEC that its Form 10-Q for the period ended March 31, 2026 will be late while it compiles information for the year ended December 31, 2025. The notification is signed by Vikram Grover and dated May 15, 2026.

Insights

Corporate Compliance Counsel

Notice of late Form 10-Q filing under Rule 12b-25.

The filing is a procedural notification under Form 12b-25 stating the company is compiling year-end information and cannot timely file its Form 10-Q for the period ended March 31, 2026. The form references relief timelines under Rule 12b-25: a five-calendar-day cure for quarterly reports and a fifteen-calendar-day cure for annual reports.

Because this is a notification, the company indicates intent to complete its report; the notification itself does not quantify financial impact or changes in operating results. Subsequent periodic filings will show any material changes.

Investor Relations Advisor

Disclosure signal: administrative delay, not an earnings restatement.

The notice attributes the delay to compiling information for the fiscal year ended December 31, 2025. It does not state changes to results of operations and includes contact information for Vikram Grover. The company checked procedural boxes on the form.

Investors should await the actual Form 10-Q for any material financial details; the 12b-25 filing itself is a routine regulatory step indicating a timing issue rather than a disclosed material adjustment.

Key Figures

Quarter period end: March 31, 2026 Year-end being compiled: December 31, 2025 Notification date: May 15, 2026 +2 more

5 metrics

Quarter period end March 31, 2026 Period covered by the late Form 10-Q

Year-end being compiled December 31, 2025 Fiscal year for which information is being compiled

Notification date May 15, 2026 Date the Form 12b-25 was signed

Cure periods cited five / fifteen calendar days Rule 12b-25 cure periods for quarterly and annual reports

Contact phone (630) 708-0750 Contact for notification listed on form

Key Terms

Form 12b-25, Rule 12b-25(b), Form 10-Q

3 terms

Form 12b-25 regulatory

"filed a Form 12b-25 notifying the SEC"

Form 12b-25 is a notice a publicly traded company files with the U.S. Securities and Exchange Commission when it cannot deliver a required periodic report (like a quarterly or annual financial report) on time. It explains the reason for the delay and gives the company a short, temporary window to finish the report without being marked as delinquent; investors watch it because late filings can signal accounting, operational, or control issues that may affect a company’s reliability and stock risk, much like a missed homework deadline can raise concerns about a student’s preparedness.

Rule 12b-25(b) regulatory

"seeks relief pursuant to Rule 12b-25(b)"

Form 10-Q regulatory

"the subject Quarterly report on Form 10-Q"

A Form 10-Q is a detailed report that publicly traded companies are required to file with regulators three times a year, providing an update on their financial health and business activities. It is important for investors because it offers timely insights into a company's performance, helping them make informed decisions about buying or selling stocks. Think of it as a regular check-up report that shows how well a company is doing.

FAQ

What does Bio-Path Holdings' Form 12b-25 mean for BPTH shareholders?

It means the company has notified regulators of a late Form 10-Q filing for the period ended March 31, 2026. The notice explains the delay is due to compiling year-end information and is signed by Vikram Grover on May 15, 2026.

Will Bio-Path receive relief to file the late Form 10-Q?

The company invoked the procedural provisions of Rule 12b-25, which provides a cure period (five calendar days for quarterly reports). The form indicates an intent to complete filing within the rule’s timelines; actual relief depends on meeting those procedural deadlines.

Does the 12b-25 notice state any change in Bio-Path’s results of operations?

No. The notice includes a question about significant changes in results and the form records the company’s response, but it does not provide specific financial figures or state that operating results will change compared with the prior year period.

Who can investors contact about this late filing for BPTH?

The notice lists Vikram Grover as the contact with phone number (630) 708-0750. This is the designated contact for inquiries regarding the late Form 10-Q for the period ended March 31, 2026.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/15/2026 - 12:28 PM Learn about SEC filing dates

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

FORM 12b-25

NOTIFICATION OF LATE FILING

(Check One) ☐ Form 10-K ☐ Form 20-F ☐ Form 11-K ☒ Form 10-Q ☐ Form 10-D ☐ Form N-SAR

☐ Form N-CSR

For the Period Ended: March 31, 2026

☐	Transition Report on Form 10-K
☐	Transition Report on Form 20-F
☐	Transition Report on Form 11-K
☐	Transition Report on Form 10-Q
☐	Transition Report on Form N-SAR

For the Transition Period Ended:

Nothing in this Form shall be construed to imply that the Commission has verified any information contained herein.

If the notification relates to a portion of the filing checked above, identify the Item(s) to which the notification relates:

PART I - REGISTRANT INFORMATION

Full Name of Registrant: Bio-Path Holdings, Inc..

Former Name, if Applicable: n/a

Address of Principal Executive Office (Street and Number):

625 Stanwix St. #2407

Pittsburgh, Pennsylvania 15222

PART II - RULES 12b-25 (b) AND (c)

If the subject report could not be filed without reasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following should be completed. (Check box if appropriate)

☐ (a) The reasons described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense;

☒ (b) The subject annual report or semi-annual report, transition report on Form 10-K, Form 20-F, 11-K or Form N-SAR, or portion thereof will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject Quarterly report or transition report on Form 10-Q, or portion thereof, will be filed on or before the fifth calendar day following the prescribed due date; and

☐ (c) The accountant’s statement or other exhibit required by Rule 12b-25(c) has been attached if applicable)

PART III - NARRATIVE

The Registrant is in the process of compiling information for the year ending December 31, 2025 for the Form 10-K, all of which information has not yet been received.

PART IV - OTHER INFORMATION

(1) Name and telephone number of person to contact in regard to this notification:

Vikram Grover (630) 708-0750.

(2) Have all or other periodic report required under section 13 or 15(d) of the Securities Exchange Act of 1934 or section 30 of the Investment Company act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s) been filed? If the answer is no, identify report(s).

☒ Yes ☐ No

(3) Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof?

☐ Yes ☒ No

The Registrant has caused this notification to be signed on its behalf by the undersigned, thereunto duly authorized.

Bio-Path Holdings, Inc.

Vikran Grover

Chief Executive Officer and Chief Financial Officer

625 Stanwix St. #2407

Pittsburgh, Pennsylvania 15222

Dated: May 15, 2026

ATTENTION

Intentional misstatements or omissions of fact constitute Federal Criminal Violations (See 18 U.S.C. 1001).